| 专利名称 | FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION | ||
| 申请号 | US16494962 | 申请日 | |
| 公开（公告）号 | US20200010554A1 | 公开（公告）日 | |
| 申请（专利权）人 | Tusk Therapeutics Ltd; Cancer Research Technology Limited | 发明人 | Anne Goubier; Josephine Salimu; Kevin Moulder; Beatriz Goyenechea Corzo; Pascal Merchiers; Sergio Quezada; Karl Peggs; Frederick Arce Vargas; Isabelle Solomon |
| 专利来源 | 国家知识产权局 | 转化方式 | |
| 摘要 |
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection. |
||
主管部门：海南中小企业服务 | 建设单位：海南商业联合会
版权所有：海南商业联合会 | 备案号：粤ICP备13083911号（ICP加挂服务）@2017
